Please use this identifier to cite or link to this item:
Title: Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients
Authors: Inaoka, Riguel J. [UNIFESP]
Jungbluth, Achim A.
Gnjatic, Sacha
Ritter, Erika
Hanson, Nicole C.
Frosina, Denise
Tassello, Jodie
Etto, Leina Y. [UNIFESP]
Bortoluzzo, Adriana B.
Alves, Antonio C. [UNIFESP]
Colleoni, Gisele W. B. [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Mem Sloan Kettering Canc Ctr
Inst Ensino & Pesquisa
Keywords: Non-Hodgkin's lymphoma
Cancer/testis antigens
Humoral response
Issue Date: 1-Dec-2012
Publisher: Springer
Citation: Cancer Immunology Immunotherapy. New York: Springer, v. 61, n. 12, p. 2207-2214, 2012.
Abstract: Based on their tumor-associated expression pattern, cancer/testis antigens (CTAs) are considered potential targets for cancer immunotherapy. We aim to evaluate the expression of CTAs in non-Hodgkin's lymphoma (NHL) samples and the ability of these patients to elicit spontaneous humoral immune response against CTAs.Expression of MAGE-A family, CT7/MAGE-C1, CT10/MAGE-C2, GAGE and NY-ESO-1 was analyzed by immunohistochemistry in a tissue microarray generated from 106 NHL archival cases. the humoral response against 19 CTAs was tested in 97 untreated NHL serum samples using ELISA technique.11.3 % of NHL tumor samples expressed at least 1 CTA. MAGE-A family (6.6 %), GAGE (5.7 %) and NY-ESO-1(4.7 %) were the most frequently expressed antigens. We found no statistically significant correlation between CTA positivity and clinical parameters such as NHL histological subtype, Ann Arbor stage, international prognostic index score, response to treatment and overall survival. Humoral response against at least 1 CTA was observed in 16.5 % of NHL serum samples. However, overall seroreactivity was low, and strong titers (> 1:1000) were observed in only two diffuse large B-cell lymphomas patients against CT45.Our findings are in agreement with most of published studies in this field to date and suggest an overall low expression of CTAs in NHL patients. However, as many new CTAs have been described recently and some of them are found to be highly expressed in NHL cell lines and tumor samples, further studies exploring the expression of different panels of CTAs are needed to evaluate their role as candidates for immunotherapy in NHL patients.
ISSN: 0340-7004
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.